Parkway Cancer Centre
Gleneagles Medical Centre
6 Napier Road #03-01
Tel: (+65) 6472 0800
MBBS (Malaya), MRCP (United Kingdom), FRCPath (United Kingdom)
Dr Lee Yuh Shan is a senior consultant haematologist specialising in malignant haematology such as lymphoma, leukaemia, myeloma and haematopoietic stem cells transplant. He received his basic medical degree from University of Malaya in 2003 and Membership of The Royal College of Physician (MRCP) in 2007. He completed his haematology training at Singapore General Hospital (SGH) in 2011 and subsequently obtained his Fellowship of the Royal College of Pathologists (FRCPath), United Kingdom in 2013. He was awarded Health Manpower Development Programme (HMDP) fund in 2013, under Ministry of Health, to further develop his specialty in lymphoma at National Institutes of Health (NIH), Maryland, United States.
During this period, he had first-hand experience on seeing patients under clinical trial with new oral therapy in the treatment of chronic lymphocytic leukemia (CLL) as well as on aggressive lymphoma. In particular, National Cancer Institute (NCI) at the NIH has extensive experience in aggressive lymphoma. It is also during this period that he developed his skills in the new treatment approach for Primary Central Nervous System Lymphoma (PCNSL). After his return from HMDP, he contributed to the development and incorporation of new agents in the treatment of lymphoma, as well as on the development of investigator-initiated trials for aggressive lymphoma in the Department of Haematology, SGH.
Dr Lee worked for ten years in SGH and received Gold and Star awards in 2013 and 2017 respectively, under Singapore Health Quality Service Awards. He was the director of lymphoma service in Department of Haematology, SGH from 2017 and lymphoma lead in SingHealth Duke Blood Cancer Centre (SDBCC) from 2018. During this period, he oversaw hundreds of patients treated for haematological condition. He is active in collaborative works locally under the SDBCC and Singapore Lymphoma Working Group; as well as regionally for Chronic Lymphocytic Leukemia (CLL). In addition, he is involved in many pharmaceutical sponsored trials and investigator-initiated trials, most of these trials focus on new agents in lymphoma and myeloma. He has published in many peer-reviewed journals and is a reviewer for peer-reviewed journals. He is also a member of SingHealth Institutional Review Board (IRB) and sat on several pharmaceutical advisory boards.
Dr Lee is active in undergraduate medical training and is a senior clinical tutor for Yong Loo Lin School of Medicine and Adjunct Associate Professor for Duke NUS School of Medicine. He is also a faculty member of the senior residency program in haematology, SGH. Regionally, he is active and speaks in many regional haematology symposiums especially in CLL/lymphoma. He contributes to lymphoma support group and Singapore World Lymphoma Day.